2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Bleeding and Clotting, Thromboembolism, Thrombocytopenias, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, MPN, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Pediatric, Pregnant
PAPER

4867 Safety of anticoagulation in patients with liver cirrhosis and severe thrombocytopenia: A propensity score-matched cohort study

Kok Hoe Chan, MD, Jennifer Elizabeth Collins, PhD2
1 Charleston Area Medical Center, Charleston, West Virginia, United States
2 Charleston Area Medical Center, Charleston, West Virginia, United States

Background: Patients with severe thrombocytopenia (platelet count <50,000/μL) frequently have concurrent indications for anticoagulation, including venous thromboembolism (VTE), atrial fibrillation, portal vein thrombosis, or mechanical heart valves. However, anticoagulation in this population remains challenging because of the competing risks of bleeding and thrombosis, and current recommendations are based on limited evidence. Patients with liver cirrhosis represent a particularly complex population due to alterations in hemostasis that may increase both bleeding and thrombotic risk. We evaluated the safety and outcomes of anticoagulation in patients with liver cirrhosis and severe thrombocytopenia using a large real-world database.

Methods: This retrospective cohort study utilized de-identified electronic health record data from the TriNetX Research Network from 2010-2015. Adults with liver cirrhosis, at least two platelet counts <50,000/μL, and a documented indication for anticoagulation (VTE, atrial fibrillation, portal vein thrombosis, or mechanical heart valve) were included. Patients receiving anticoagulation were compared with those not receiving anticoagulation after 1:1 propensity score matching. Risk ratios (RRs) were calculated for binary outcomes while Kaplan-Meier log rank analyses were used for survival. The primary outcome was major bleeding. Secondary outcomes included all-cause mortality, clinically relevant non-major bleeding (CRNMB), VTE, and outcomes according to anticoagulant class.

Results: A total of 3,584 patients with liver cirrhosis met the inclusion criteria. After 1:1 propensity score matching, 1,792 patients remained in each cohort. Anticoagulation was associated with significantly higher 90-day mortality (43.4% vs. 33.2%; RR = 1.305, 95% CI: 1.20–1.42; p<0.001). Ninety-day survival (53.4% vs. 64.3%; HR = 1.37; p<0.001) and 1-year survival (38.9% vs. 47.9%; HR = 1.30; p<0.001) were also significantly lower in the anticoagulated cohort. Major bleeding was significantly more common among anticoagulated patients (18.2% vs. 15.3%; p=0.020), whereas VTE (18.9% vs. 16.4%; p=0.054) and CRNMB (4.6% vs. 3.9%; p=0.280) were not significantly different. In subgroup analyses, heparin (1,393 matched pairs) was associated with significantly worse survival and higher rates of major bleeding, VTE, and CRNMB. LMWH-based anticoagulants (245 matched pairs) demonstrated no significant differences in mortality, survival, major bleeding, VTE, or CRNMB compared with no anticoagulation. DOACs (106 matched pairs) showed no significant differences in mortality or thrombotic outcomes and were associated with a lower rate of major bleeding (13.2% vs. 24.5%; p=0.035). There were insufficient warfarin users for meaningful subgroup analysis.

Conclusions: This study addresses an important evidence gap regarding anticoagulation in patients with liver cirrhosis and severe thrombocytopenia. Overall anticoagulation was associated with increased mortality and major bleeding in this real-world cohort. However, exploratory subgroup analyses suggest that LMWH and DOACs may have more favorable safety profiles than unfractionated heparin, although these findings should be interpreted cautiously due to the small sample size and the possibility of residual confounding inherent to observational data. Prospective studies are needed to better define the optimal anticoagulation strategy in this high-risk population.

Kok Hoe Chan, MD: No relevant conflicts of interest to declare.